Evolving Horizons in HER2-Positive Breast Cancer Care

Over the past five years, the treatment landscape for HER2-positive breast cancer has advanced significantly across both early-stage and metastatic settings. In early disease, clinicians have benefited from increasingly refined, targeted approaches that improve cure rates while reducing treatment burden. For metastatic disease, novel agents and optimized sequencing strategies have expanded long-term disease control and improved quality of life. Looking ahead, the next five years promise even more transformative progress. Continued innovation is expected to personalize therapy even further, leveraging biomarkers, novel antibody-drug conjugates, and smarter combinations to extend survival and minimize toxicity. Both early and metastatic HER2-positive breast cancer are poised to move toward more individualized, less intensive, and more durable treatment strategies, reshaping outcomes for patients across the continuum of care.